603 related articles for article (PubMed ID: 22166172)
1. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
Maayan L; Correll CU
J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
[TBL] [Abstract][Full Text] [Related]
3. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
4. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.
Cohen D; Bonnot O; Bodeau N; Consoli A; Laurent C
J Clin Psychopharmacol; 2012 Jun; 32(3):309-16. PubMed ID: 22544019
[TBL] [Abstract][Full Text] [Related]
5. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.
Zuddas A; Zanni R; Usala T
Eur Neuropsychopharmacol; 2011 Aug; 21(8):600-20. PubMed ID: 21550212
[TBL] [Abstract][Full Text] [Related]
6. Off-label second generation antipsychotics for impulse regulation disorders: a review.
Scheltema Beduin A; de Haan L
Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
[TBL] [Abstract][Full Text] [Related]
8. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
9. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.
Hasnain M; Vieweg WV; Hollett B
Postgrad Med; 2012 Jul; 124(4):154-67. PubMed ID: 22913904
[TBL] [Abstract][Full Text] [Related]
10. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Correll CU; Manu P; Olshanskiy V; Napolitano B; Kane JM; Malhotra AK
JAMA; 2009 Oct; 302(16):1765-73. PubMed ID: 19861668
[TBL] [Abstract][Full Text] [Related]
11. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.
Correll CU
J Clin Psychiatry; 2008; 69 Suppl 4():26-36. PubMed ID: 18533766
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
Ellinger LK; Ipema HJ; Stachnik JM
Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
[TBL] [Abstract][Full Text] [Related]
13. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Baptista T; Kin NM; Beaulieu S; de Baptista EA
Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
[TBL] [Abstract][Full Text] [Related]
14. Hyperglycemia and antipsychotic medications.
Haupt DW; Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
[TBL] [Abstract][Full Text] [Related]
15. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
[TBL] [Abstract][Full Text] [Related]
16. Effects of second generation antipsychotics on leptin and ghrelin.
Esen-Danaci A; Sarandöl A; Taneli F; Yurtsever F; Ozlen N
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1434-8. PubMed ID: 18579280
[TBL] [Abstract][Full Text] [Related]
17. Experimental antipsychotics and metabolic adverse effects--findings from clinical trials.
Tschoner A; Fleischhacker WW; Ebenbichler CF
Curr Opin Investig Drugs; 2009 Oct; 10(10):1041-8. PubMed ID: 19777392
[TBL] [Abstract][Full Text] [Related]
18. The implications of weight changes with antipsychotic treatment.
Sussman N
J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
[TBL] [Abstract][Full Text] [Related]
19. Naturalistic impact of second-generation antipsychotics on weight gain.
Brixner DI; Said Q; Corey-Lisle PK; Tuomari AV; L'italien GJ; Stockdale W; Oderda GM
Ann Pharmacother; 2006 Apr; 40(4):626-32. PubMed ID: 16569802
[TBL] [Abstract][Full Text] [Related]
20. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.
Stigler KA; Potenza MN; Posey DJ; McDougle CJ
Paediatr Drugs; 2004; 6(1):33-44. PubMed ID: 14969568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
